CRISPR Therapeutics is led by a seasoned management team focused on translating CRISPR/Cas9 technology into transformative gene-based medicines for patients with serious diseases. We are working in parallel with our world-class group of scientific founders and advisors, who have extensive experience in gene editing, stem cell biology, advanced drug delivery technologies, RNAi and gene silencing.
Dr. Rodger Novak co-founded CRISPR Therapeutics together with Emmanuelle Charpentier and Shaun Foy. He is an experienced pharmaceutical and biotechnology executive and former University Professor at the Vienna Biocenter in Austria. He brings a combination of scientific experience, gained through his academic career, and a proven track record of successfully translating technologies into pharmaceutical products.
In his most recent position, Rodger was Global Head, Anti-Infectives Research & Development at Sanofi, where he was responsible for small molecule and biologics R&D, including early drug discovery and clinical development. Before that he was a founder of Nabriva Therapeutics and served as its Chief Operating Officer for almost six years. He started his pharmceutical career at Sandoz (Novartis), where he was appointed as the deputy Head of the Antibiotic Research Institute.
Rodger received his M.D. from the Philipps University in Marburg, Germany in 1993 and his foreign medical license for the U.S. in 1994. He was a postdoctoral fellow at The Rockefeller University, St. Jude Children’s Research Hospital and the Skirball Institute NYU Medical Center. During his academic career Rodger authored numerous publications, among them articles in Nature, Nature Medicine and Molecular Cell. Rodger is co-inventor of five patents.
Dr. Samarth Kulkarni has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He was previously a Partner at McKinsey and Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, Sam co-led the biotech practice and served a number of biotechnology companies on topics ranging from strategy to operations. Additionally, he led initiatives in areas such as personalized medicine and immunotherapy, where he co-authored several publications.
Sam received his Ph.D. in bioengineering and nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics, and published in numerous leading journals.
Dr. Tony Ho is a highly accomplished R&D leader with experience across all phases of R&D, including: discovery, early and late-stage clinical development, and regulatory, throughout his nearly 20 year career. He was previously Senior Vice President and Head of Oncology Integration and Innovation at AstraZeneca. During his tenure at AstraZeneca, he oversaw both development and commercialization of the two key drugs – Lynparza, a first-in-class PARP inhibitor for ovarian cancer and Imfinizi (anti-PD-L1), AstraZeneca’s first immuno-oncology drug for bladder cancer. For both drugs, he led the program through filing, regulatory defense, payer access, and commercial launch, and initiated Phase III development across multiple tumor types. Prior to joining AstraZeneca, Tony was the Neurology and Ophthalmology Clinical Section Head at Merck Research Laboratories, Merck & Co., Inc. and led multiple development programs including the approval of Maxalt for pediatric migraine and Zioptan for glaucoma. Prior to joining Merck, Tony was the Co-Founder and Chief Scientific Officer of Neuronyx, Inc., a regenerative medicine company.
Tony completed his B.S. in Electrical Engineering at the University of California, Los Angeles, and received his M.D. from the Johns Hopkins University School of Medicine. After an internship in Internal Medicine at the Massachusetts General Hospital, Tony completed his residency and neurophysiology fellowship in the Department of Neurology at the Johns Hopkins Hospital. He was Assistant Professor at Johns Hopkins Hospital in the areas of neuropathy and neuromuscular diseases. He has published widely in several fields with over 80 papers and is co-inventor of seven patents. He is currently adjunct Associate Professor of Neurology at University of Pennsylvania and Assistant Professor of Neurology at Johns Hopkins University.
Dr. Bill Lundberg has extensive experience across all aspects and phases of drug development in both academic and industry settings. He was previously Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, where he was responsible for all R&D from discovery to clinical proof-of-concept. Before that, Bill held senior positions at Taligen Therapeutics, Antisoma, Xanthus (acquired by Antisoma), Wyeth (now Pfizer) and Genzyme, overseeing the development of diverse portfolios.
Bill received his B.S. in biology from the Massachusetts Institute of Technology (MIT), M.D. from Stanford Medical School and M.B.A. from the University of Massachusetts Amherst. As a post-doctoral fellow he studied at the Whitehead Institute at MIT, and trained in internal medicine and oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.
Dr. Tyler Dylan-Hyde has more than two decades of experience both in law firms and in-house for privately-held and public companies developing gene-based therapeutics and other technologies.
Tyler was a Partner at Morrison & Foerster LLP, specializing in the development and defense of global IP portfolios, licensing and corporate transactions. As in-house general counsel, he helped lead Collateral Therapeutics, which had an IPO on NASDAQ and was later acquired by Schering AG (now Bayer Healthcare Pharmaceuticals), InnerCool Therapies, which was advanced through FDA clearance and acquired by Philips Healthcare, and Cardium Therapeutics, which developed a portfolio of companies, some acquired and others currently in partnership.
Tyler received his B.Sc. in cell, molecular and developmental biology from McGill University, Montreal, Canada, his Ph.D. in biology from the University of California, San Diego, and his J.D. from the University of California, Berkley (Boalt Hall School of Law). He is a co-inventor of several patent applications and a co-author of a number of scientific publications.
Jim Kasinger has nearly 20 years of experience advising and counseling private and public companies in the biotechnology and technology sectors. Prior to joining the company, Jim was the General Counsel and Secretary of Moderna Therapeutics, a Cambridge-based biotechnology company, where, among other things, he helped lead two equity financings (raising nearly $1 billion) and several collaborations including with AZ, Merck and Vertex. Before that, Jim was the General Counsel at PlumChoice, Inc., a provider of technical support services to Fortune 1000 companies. Before going in-house, Jim was a partner in the Business Practice Group at the global law firm, Goodwin Procter LLP, where he represented life sciences, technology and other high-growth companies in all stages of their life cycles, from formation, to obtaining seed and growth financings, to initial public offering, merger or sale. Jim started his legal career as an associate at Testa, Hurwitz & Thibeault.
Jim received his J.D. from Boston College Law School, graduating cum laude, and a B.A. from Wheaton College, graduating magna cum laude.
Dr. Kala Subramanian has extensive experience in Strategic Planning, Portfolio and Program management across early and late stage development in Oncology and other therapeutic areas. In her most recent position, Kala was Vice President and Global Head of Strategic Development & Program Management at Novartis Pharmaceuticals (Oncology), where she was responsible for program and portfolio management, strategic planning, resource allocation and management of budget. She was also responsible for the integration of GSK Oncology into Novartis including full alignment of the portfolio, organization & people. Before that, Kala was in program management at Millennium and a senior consultant at Accenture.
Kala received her PhD in Physical Chemistry from Cornell University and was a post-doctoral fellow at Duke University Medical Center.
Megan Wherry Menner has extensive HR experience in the pharmaceutical, biotech and life sciences industries. She was previously with Merck KGaA for eight years, most recently as Vice President and Head of HR for the global €4.6B Merck Millipore Life Science business. In this role, Megan was responsible for HR strategy, business partnership and all HR functions aligned to the Life Science business, including the people and organization integration of the Sigma-Aldrich acquisition. Also at Merck KGaA, Megan served as VP and Head of HR International where she had responsibility for all HR team members in 60+ countries as well as VP and Head of HR for EMD Serono, where she led all HR functions for the $1.2B US Pharma business.
Before that, Megan spent five years at Novartis through a period of rapid growth, most recently serving as Head of Talent and Culture Development for the entire Research organization globally, and held several senior HR business partner roles in the US and in the UK. Megan also worked in Leadership Development at Amgen and HR Business Partnership at Bristol-Myers Squibb and earlier in her career in Talent Acquisition at a software start-up company as an outgrowth of MIT Sloan Business School that was acquired by Lucent Technologies.
Megan earned both her Bachelor’s degree in Psychology and Economics and her Master’s degree in Human Resources and Organizational Behavior from Cornell University.
Dr. Jon Terrett has an extensive track record for discovering and progressing immuno-oncology drug candidates into the clinic. Prior to joining CRISPR Therapeutics, Jon was the Vice President of oncology discovery for CytomX, a U.S.-based biotechnology company focused on developing drugs to treat different types of cancer. In addition, Jon has held various R&D leadership roles in biopharma, including serving as the Chief Scientific Officer at Oxford Biotherapeutics, and as a director at various biotechnology companies including Medarex, CellTech and Oxford Glycosciences.
Jon received a B.S. in genetics at the University of Sheffield and a doctorate in genetics at the University of Nottingham.